The Role of Aberrant DNA Methylation in Misregulation of Gene Expression in Gonadotroph Nonfunctioning Pituitary Tumors.
DNA methylation
NFPA
adenoma
epigenetics
gene expression
gonadotrophinoma
pituitary
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Oct 2019
25 Oct 2019
Historique:
received:
05
09
2019
revised:
18
10
2019
accepted:
21
10
2019
entrez:
17
11
2019
pubmed:
17
11
2019
medline:
17
11
2019
Statut:
epublish
Résumé
Gonadotroph nonfunctioning pituitary adenomas (NFPAs) are common intracranial tumors, but the role of aberrant epigenetic regulation in their development remains poorly understood. In this study, we investigated the effect of impaired CpG methylation in NFPAs. We determined DNA methylation and transcriptomic profiles in 32 NFPAs and normal pituitary sections using methylation arrays and sequencing, respectively. Ten percent of differentially methylated CpGs were correlated with gene expression, and the affected genes are involved in a variety of tumorigenesis-related pathways. Different proportions of gene body and promoter region localization were observed in CpGs with negative and positive correlations between methylation and gene expression, and different proportions of CpGs were located in 'open sea' and 'shelf/shore' regions. The expression of ~8% of genes differentially expressed in NFPAs was related to aberrant methylation. Methylation levels of seven CpGs located in the regulatory regions of
Identifiants
pubmed: 31731486
pii: cancers11111650
doi: 10.3390/cancers11111650
pmc: PMC6895980
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Maria Sklodowska-Curie Institute - Oncology Center
ID : internal grant SN/GW27/2017
Références
Front Endocrinol (Lausanne). 2019 May 14;10:290
pubmed: 31139150
PLoS One. 2014 Apr 29;9(4):e96178
pubmed: 24781529
Epigenetics. 2018;13(4):386-397
pubmed: 29697014
BMC Med Genet. 2017 Jul 14;18(1):72
pubmed: 28709401
Mol Cell Endocrinol. 2010 Sep 15;326(1-2):19-24
pubmed: 20347930
Endocr Relat Cancer. 2006 Sep;13(3):707-16
pubmed: 16954426
PLoS One. 2013 Dec 18;8(12):e82619
pubmed: 24367530
Mol Cell Endocrinol. 2018 Jul 5;469:70-76
pubmed: 28711607
Clin Cancer Res. 2018 Sep 1;24(17):4126-4136
pubmed: 30084836
Bioinformatics. 2014 Feb 01;30(3):428-30
pubmed: 24336642
BMC Bioinformatics. 2015;16 Suppl 5:S10
pubmed: 25861082
Brief Funct Genomics. 2018 Mar 1;17(2):104-115
pubmed: 29579165
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Endocrinology. 2012 Aug;153(8):3603-12
pubmed: 22700770
Genome Biol. 2013 Sep 24;14(9):r105
pubmed: 24063430
PLoS Comput Biol. 2013;9(8):e1003118
pubmed: 23950696
Cold Spring Harb Perspect Biol. 2016 Sep 01;8(9):
pubmed: 27194046
Genome Biol. 2014;15(12):550
pubmed: 25516281
Pituitary. 2016 Feb;19(1):110-2
pubmed: 25893614
Mol Cell Endocrinol. 2018 Sep 15;473:194-204
pubmed: 29410024
Oncogene. 2019 Jan;38(4):497-517
pubmed: 30115975
Epigenetics. 2016 Mar 3;11(3):237-46
pubmed: 26929985
J Neurooncol. 2007 Jun;83(2):153-62
pubmed: 17216555
Pituitary. 2015 Oct;18(5):674-84
pubmed: 25557289
Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):625-38
pubmed: 19945027
J Clin Endocrinol Metab. 2013 Apr;98(4):E796-800
pubmed: 23450047
J Clin Endocrinol Metab. 2019 Apr 1;104(4):1272-1282
pubmed: 30423170
Science. 2007 Feb 23;315(5815):1141-3
pubmed: 17322062
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Endocr Relat Cancer. 2012 Nov 19;19(6):805-16
pubmed: 23045325
Cell Physiol Biochem. 2016;40(3-4):757-769
pubmed: 27915333
Open Biol. 2017 Jan;7(1):
pubmed: 28123054
Mol Med Rep. 2015 Aug;12(2):2411-6
pubmed: 25936862
J Neurooncol. 2016 Aug;129(1):23-31
pubmed: 27168190
Oncogene. 2012 Aug 23;31(34):3857-65
pubmed: 22139073
Oncotarget. 2016 May 10;7(19):28540-55
pubmed: 27081034
Lab Invest. 2005 Apr;85(4):464-73
pubmed: 15711568
Nat Rev Genet. 2007 Apr;8(4):286-98
pubmed: 17339880
Cancer Cell. 2014 Oct 13;26(4):577-90
pubmed: 25263941
Front Genet. 2015 May 18;6:182
pubmed: 26042147